All In Biotech

Drug Trial Radar · NCT06016842

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

276

Planned (sponsor's estimate)

Start

Aug 31, 2023

Primary completion

May 31, 2029

Study completion May 31, 2029

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Aug 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment) and will last up to 3.5 years for each participant. The main aim of this study is to determine if elafibranor is better than placebo in preventing clinical outcome events showing disease worsening (including progression of disease leading to liver transplant or death). This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itching and tiredness.

Conditions

  • Primary Biliary Cholangitis (PBC)

Interventions

  • ElafibranorDrug

    Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily

  • Matched 80 mg placeboOther

    Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which matching placebo tablet will be administered once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survivalTime frame: From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)

Locations

198 sites in 28 countries. Site status is shown where the registry gives one.

  • Arizona Liver Health

    Tucson, Arizona · Recruiting

  • Arkansas Diagnostic Center, PA

    Little Rock, Arkansas · Terminated

  • Southern California Research Center

    Coronado, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Withdrawn

  • GastroIntestinal BioSciences

    Los Angeles, California · Active not recruiting

  • University of California Los Angeles

    Los Angeles, California · Withdrawn

  • University of California Davis Medical Center

    Sacramento, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado · Recruiting

  • South Denver Gastroenterology, P.C.

    Englewood, Colorado · Active not recruiting

  • Rocky Mountain Gastroenterology

    Littleton, Colorado · Recruiting

  • University Of Miami School Of Medicine, Center For Liver Diseases

    Miami, Florida · Recruiting

  • Bolanos Clinical Research

    Pembroke Pines, Florida · Recruiting

  • International Center for Research

    Tampa, Florida · Recruiting

  • University of Kansas Medical Center (KUMC) - University of Kansas Liver Center - Hepatology Clinic

    Kansas City, Kansas · Not yet recruiting

  • Louisiana Research Center, LLC

    Shreveport, Louisiana · Recruiting

  • University of Michigan Health System

    Ann Arbor, Michigan · Recruiting

  • Huron Gastroenterology Associates - Center for Digestive Care

    Ypsilanti, Michigan · Withdrawn

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Southwest Gastroenterology Associates, PC (SWGA)

    Albuquerque, New Mexico · Terminated

  • NYU Langone Gastroenterology and Hepatology Associates

    New York, New York · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Gastroenterology Center of the Midsouth

    Cordova, Tennessee · Recruiting

  • Texas Clinical Research Institute

    Arlington, Texas · Recruiting

  • American Research Corporation

    Austin, Texas · Recruiting

  • Rush University Medical Center - University Cardiovascular Surgeons

    Dallas, Texas · Withdrawn

  • Liver Center of Texas

    Dallas, Texas · Terminated

  • Methodist Transplant Physicians

    Dallas, Texas · Recruiting

  • University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas · Recruiting

  • Baylor Scott & White All Saints Medical Center - Forth Worth

    Fort Worth, Texas · Withdrawn

  • Liver Associates of Texas

    Houston, Texas · Recruiting

  • Houston Methodist Cancer Center

    Houston, Texas · Active not recruiting

  • Gastro health & Nutrition

    Katy, Texas · Terminated

  • American Research Corporation at The Texas Liver Institute

    San Antonio, Texas · Recruiting

  • Starhope Liver Center, PA - Starhope Clinical Research, LLC

    San Antonio, Texas · Recruiting

  • Impact Research Tx

    Waco, Texas · Withdrawn

  • University of Virginia Medical Center

    Charlottesville, Virginia · Recruiting

  • Bon Secours St. Mary's Hospital of Richmond, Inc

    Richmond, Virginia · Recruiting

  • Virginia Commonwealth University Medical Center - West Hospital

    Richmond, Virginia · Not yet recruiting

Showing 40 of 198 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.